Lin MH, et al. Real-world brigatinib use in non-small cell lung cancer patients with prior use of crizotinib/other ALK therapies in the US. Abstract P2.16-09. WCLC 2019, 7-10 sept. Barcelona, Spanje.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker